Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vorasidenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 known ✓ | O75874 | 20/20 | 1.00 |
| ▸ | IDH2 known ✓ | P48735 | 10/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vorasidenib SCHEMBL17971596 | 1.00 | IDH1 (1.00) | IDH1IDH2 | |
| Vorasidenib SCHEMBL16393055 | 1.00 | IDH1 (1.00) | IDH1IDH2 | |
| Vorasidenib SCHEMBL29599150 | 1.00 | IDH1 (1.00) | IDH1IDH2 | |
| Vorasidenib SCHEMBL29422965 | 1.00 | IDH1 (1.00) | IDH1IDH2 | |
| Vorasidenib SCHEMBL16393169 | 1.00 | IDH1 (1.00) | IDH1IDH2 | |
| Vorasidenib SCHEMBL16393139 | 1.00 | IDH1 (1.00) | IDH1IDH2 | |
| Vorasidenib SCHEMBL16393154 | 1.00 | IDH1 (1.00) | IDH1IDH2 | |
| SCHEMBL17971621 | 0.96 | IDH1 (0.92) | IDH1IDH2 | |
| SCHEMBL17971623 | 0.96 | IDH1 (0.92) | IDH1IDH2 | |
| SCHEMBL17971622 | 0.96 | IDH1 (0.92) | IDH1IDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107194-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107194-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | IDH1 172/4885IDH2 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.